NCT02692677View on ClinicalTrials.gov

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Healthy

Interventions

DRUG

JNJ-42756493

Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.

Trial Locations (1)

Unknown

Madison

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02692677 - A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants | Biotech Hunter | Biotech Hunter